fda glp-1 compounding crackdown news october 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of medications like semaglutide and tirzepatide, signaling a major shift in how these FDA ramps up its pushback

Genetically-predicted GLP1R expression (the target of GLP-1 RAs) showed an inverse association with background [odds ratio (OR)=0.83, 95% CI, 0.710.97] and severe nonproliferative DR (OR=0.72, 95% CI, 0.530.98), and a non-significant association with overall (OR=0.97, 95% CI, 0.921.03) and proliferative DR (OR=0.98, 95% CI, 0.911.05)

Trulicity is a prescription medication used to treat type 2 diabetes. It is in the class of drugs called GLP-1 receptor agonists and works by stimulating the release of insulin and decreasing the production of sugar by the liver. The pre-filled pens come in a pack of 4 and contain a solution of dulaglutide, the active ingredient, in a concentration of 1.5 mg per 0.5 mL. These pens are used to inject Trulicity subcutaneously (under the skin) once a week and are intended for single-use only. They are convenient and easy to use, allowing patients to self-administer their medication at home

We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.

Read more and learn why this trend is gaining traction: #glp1 #professionalskincare

No stimulants